Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
Menarini’s subsidiary Stemline will receive upfront and milestone payments, with a potential value exceeding $500m, along with royalties from sales.
Tango received US Food and Drug Administration (FDA) clearance on its investigational new drug application for TNG348 in September 2023.
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
This signifies the third submission in four months from J&J for the Rybrevant development programme.
As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital.
Give your business an edge with our leading industry insights.
Sudo plans to advance two tyrosine kinase 2 (TYK2) candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.
Bluebird bio will secure up to $250m after a surprise decision from the US Food and Drug Administration (FDA) to hold back a priority review voucher.
The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.
The companies will prioritise challenging drug targets across multiple therapy areas, leveraging Anagenex’s AI platform.
Illumina aims to finalise the terms of this divestiture by the end of the second quarter of 2024.